Bristol Myers reports data from Phase 3 DAYBREAK trial

Bristol Myers Squibb announced new data from the Phase 3 DAYBREAK trial demonstrating that decreased rates of brain volume loss were sustained in the open-label extension, or OLE, for patients treated with Zeposia, or ozanimod, for relapsing forms of multiple sclerosis. These findings showed that patients receiving continuous Zeposia treatment for up to five years experienced low and stable rates of whole brain volume, or WBV, loss through Month 60. Additionally, findings from a separate DAYBREAK OLE safety analysis demonstrated declining or stable incidence rates of treatment-emergent adverse events, or TEAEs, with relatively low rates of infections, serious infections and opportunistic infections over more than eight years of treatment with Zeposia. These data and 12 additional abstracts will be presented at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis in Copenhagen, Denmark taking place September 18-20.